Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EWTX Edgewise Therapeutics	$14.30 -1.2%	$14.68	$10.60 ▼ $38.12	$1.50B	0.28	1.21 million shs	692,055 shs
ITOS iTeos Therapeutics	$9.96 -0.4%	$8.31	$4.80 ▼ $18.13	$381.21M	1.51	676,096 shs	992,118 shs
MESO Mesoblast	$10.44 -10.7%	$11.32	$5.78 ▼ $22.00	$1.33B	2.41	274,599 shs	437,599 shs
SPRY ARS Pharmaceuticals	$15.80 -0.7%	$14.37	$7.55 ▼ $18.51	$1.55B	0.84	1.31 million shs	1.34 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EWTX Edgewise Therapeutics	-1.17%	-6.47%	-1.99%	-39.43%	-11.62%
ITOS iTeos Therapeutics	-0.40%	-2.06%	+21.17%	+44.77%	-33.38%
MESO Mesoblast	-10.69%	-11.38%	-7.28%	-25.11%	+39.39%
SPRY ARS Pharmaceuticals	-0.69%	+2.66%	+11.11%	+27.83%	+95.54%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EWTX Edgewise Therapeutics	2.9025 of 5 stars	4.4	1.0	2.2	3.3	0.0
ITOS iTeos Therapeutics	3.3212 of 5 stars	4.1	4.0	0.6	3.3	0.6
MESO Mesoblast	2.6197 of 5 stars	3.5	3.0	3.1	0.8	0.6
SPRY ARS Pharmaceuticals	3.1892 of 5 stars	3.6	2.0	2.6	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EWTX Edgewise Therapeutics	2.78	Moderate Buy	$39.78	178.17% Upside
ITOS iTeos Therapeutics	2.14	Hold	$15.86	59.21% Upside
MESO Mesoblast	3.00	Buy	$18.00	72.41% Upside
SPRY ARS Pharmaceuticals	3.17	Buy	$31.00	96.20% Upside

Current Analyst Ratings Breakdown

Latest ITOS, EWTX, MESO, and SPRY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/5/2025	EWTX Edgewise Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$48.00
5/28/2025	ITOS iTeos Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$13.00 ➝ $12.00
5/28/2025	ITOS iTeos Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$10.00 ➝ $12.00
5/14/2025	ITOS iTeos Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$16.00 ➝ $13.00
5/14/2025	ITOS iTeos Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$12.00
5/14/2025	ITOS iTeos Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$16.00 ➝ $12.00
5/14/2025	ITOS iTeos Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/14/2025	ITOS iTeos Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
5/14/2025	ITOS iTeos Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$47.00 ➝ $9.00
5/13/2025	ITOS iTeos Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$15.00 ➝ $8.00
4/30/2025	EWTX Edgewise Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$41.00

(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	$4.84 per share	N/A
ITOS iTeos Therapeutics	$35M	10.89	N/A	N/A	$16.16 per share	0.62
MESO Mesoblast	$5.90M	226.11	N/A	N/A	$4.21 per share	2.48
SPRY ARS Pharmaceuticals	$89.15M	17.41	$0.01 per share	1,865.78	$2.64 per share	5.98

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EWTX Edgewise Therapeutics	-$133.81M	-$1.55	N/A	N/A	N/A	N/A	-30.95%	-29.45%	8/6/2025 (Estimated)
ITOS iTeos Therapeutics	-$134.41M	-$3.04	N/A	N/A	N/A	N/A	-21.37%	-18.55%	8/6/2025 (Estimated)
MESO Mesoblast	-$87.96M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/29/2025 (Estimated)
SPRY ARS Pharmaceuticals	$8M	-$0.16	N/A	N/A	N/A	-16.11%	-6.94%	-5.60%	8/5/2025 (Estimated)

Latest ITOS, EWTX, MESO, and SPRY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	SPRY ARS Pharmaceuticals	-$0.35	-$0.35	N/A	-$0.35	$7.48 million	$7.97 million
5/8/2025	Q1 2025	EWTX Edgewise Therapeutics	-$0.45	-$0.43	+$0.02	-$0.43	N/A	N/A
4/28/2025	Q1 2025	ITOS iTeos Therapeutics	-$0.94	-$0.80	+$0.14	-$0.80	$9.35 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	N/A
ITOS iTeos Therapeutics	N/A	N/A	N/A	N/A	N/A
MESO Mesoblast	N/A	N/A	N/A	N/A	N/A
SPRY ARS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EWTX Edgewise Therapeutics	N/A	20.99	20.99
ITOS iTeos Therapeutics	N/A	14.13	14.13
MESO Mesoblast	0.22	0.96	0.63
SPRY ARS Pharmaceuticals	0.30	11.00	10.74

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EWTX Edgewise Therapeutics	N/A
ITOS iTeos Therapeutics	97.16%
MESO Mesoblast	1.43%
SPRY ARS Pharmaceuticals	68.16%

Insider Ownership

Company	Insider Ownership
EWTX Edgewise Therapeutics	23.20%
ITOS iTeos Therapeutics	12.50%
MESO Mesoblast	18.80%
SPRY ARS Pharmaceuticals	33.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EWTX Edgewise Therapeutics	60	105.20 million	80.79 million	Optionable
ITOS iTeos Therapeutics	90	38.27 million	33.49 million	Optionable
MESO Mesoblast	80	127.78 million	103.76 million	Optionable
SPRY ARS Pharmaceuticals	90	98.21 million	65.31 million	Optionable

ITOS, EWTX, MESO, and SPRY Headlines

Recent News About These Companies

Eric Karas Sells 15,000 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock

June 20 at 9:17 PM | marketbeat.com

249,230 Shares in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Acquired by Advisor Resource Council

June 20 at 7:36 AM | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives $31.00 Average Target Price from Brokerages

June 19 at 1:47 AM | americanbankingnews.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Average Recommendation of "Buy" by Brokerages

June 16, 2025 | marketbeat.com

Jim Cramer on ARS Pharmaceuticals: “It’s a Great Flier”

June 15, 2025 | msn.com

ARS Pharmaceuticals (NASDAQ:SPRY) Shares Up 4.9% - Still a Buy?

June 13, 2025 | marketbeat.com

Cantor Fitzgerald Predicts SPRY FY2026 Earnings

June 11, 2025 | americanbankingnews.com

Cantor Fitzgerald Estimates SPRY FY2026 Earnings

June 10, 2025 | marketbeat.com

Two Sigma Investments LP Sells 115,987 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

June 6, 2025 | marketbeat.com

Bank of America Corp DE Has $1.70 Million Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

June 5, 2025 | marketbeat.com

Ameriprise Financial Inc. Buys 36,928 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

June 3, 2025 | marketbeat.com

ARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 5.3% - Here's Why

May 31, 2025 | marketbeat.com

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences

May 27, 2025 | globenewswire.com

Millennium Management LLC Acquires 452,532 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

May 26, 2025 | marketbeat.com

ARS Pharmaceuticals (NASDAQ:SPRY) Downgraded by Wall Street Zen to Sell

May 24, 2025 | marketbeat.com

Woodline Partners LP Purchases 133,276 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

May 24, 2025 | marketbeat.com

Northern Trust Corp Increases Stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

May 24, 2025 | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Average Recommendation of "Buy" from Analysts

May 24, 2025 | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) CFO Kathleen D. Scott Sells 50,000 Shares

May 23, 2025 | insidertrades.com

Rafferty Asset Management LLC Increases Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

May 23, 2025 | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Position Raised by Wexford Capital LP

May 21, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ITOS, EWTX, MESO, and SPRY Company Descriptions

Edgewise Therapeutics NASDAQ:EWTX

$14.30 -0.17 (-1.17%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$14.68 +0.38 (+2.66%)

As of 06/20/2025 05:56 PM Eastern

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

iTeos Therapeutics NASDAQ:ITOS

$9.96 -0.04 (-0.40%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$9.96 +0.00 (+0.05%)

As of 06/20/2025 05:02 PM Eastern

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

Mesoblast NASDAQ:MESO

$10.44 -1.25 (-10.69%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$10.46 +0.02 (+0.14%)

As of 06/20/2025 07:49 PM Eastern

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

ARS Pharmaceuticals NASDAQ:SPRY

$15.80 -0.11 (-0.69%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$15.76 -0.04 (-0.25%)

As of 06/20/2025 05:51 PM Eastern

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time